Novartis to Acquire Synnovation Therapeutics' Pan-Mutant Selective PI3Kα Inhibitor Program

Core Viewpoint - Synnovation Therapeutics has announced a definitive agreement for Novartis to acquire Pikavation Therapeutics, which includes its portfolio of PI3K inhibitor programs, notably SNV4818 [1] Company Summary - Synnovation Therapeutics is a clinical-stage biotechnology company focused on developing novel small-molecule targeted therapies in oncology and immunology [1] - Pikavation Therapeutics is a wholly-owned subsidiary of Synnovation, specializing in PI3K inhibitor programs [1] Product Summary - The acquisition includes SNV4818, which is positioned as a potentially best-in-class pan-mutant selective PI3K inhibitor [1]